Top Breast Cancer Liquid Biopsy Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Breast Cancer Liquid Biopsy Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Breast Cancer Liquid Biopsy industry players.

Breast Cancer Liquid Biopsy Market Competitive Landscape

The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth.

Top Players in Breast Cancer Liquid Biopsy Market

  • F. Hoffmann-La Roche Ltd 
  • Bio-Rad Laboratories Inc. 
  • Illumina Inc. 
  • Guardant Health Inc. 
  • QIAGEN 
  • Biocept Inc. 
  • Thermo Fisher Scientific 
  • Adaptive Biotechnologies 
  • Myriad Genetics 
  • Fluxion Biosciences Inc. 
  • Biodesix 
  • Exosome Diagnostics Inc. 
  • Epic Sciences 
  • PapGene 
  • Pathway Genomics (OME Care) 
  • Agena Bioscience 
  • MDxHealth 
  • Janssen Diagnostics 
  • Abbott 

Breast Cancer Liquid Biopsy Market

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Breast Cancer Liquid Biopsy Market size was valued at USD 511.7 Million in 2024 and is poised to grow from USD 627.85 Million in 2025 to USD 3225.62 Million by 2033, growing at a CAGR of 22.7% during the forecast period (2026–2033).

The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth. 'F. Hoffmann-La Roche Ltd ', 'Bio-Rad Laboratories Inc. ', 'Illumina Inc. ', 'Guardant Health Inc. ', 'QIAGEN ', 'Biocept Inc. ', 'Thermo Fisher Scientific ', 'Adaptive Biotechnologies ', 'Myriad Genetics ', 'Fluxion Biosciences Inc. ', 'Biodesix ', 'Exosome Diagnostics Inc. ', 'Epic Sciences ', 'PapGene ', 'Pathway Genomics (OME Care) ', 'Agena Bioscience ', 'MDxHealth ', 'Janssen Diagnostics ', 'Abbott '

The increasing adoption of liquid biopsy techniques is a significant driver in the global breast cancer liquid biopsy market. Compared to traditional tissue biopsies, liquid biopsies allow for the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers present in blood samples, enabling healthcare professionals to make more informed treatment decisions. Additionally, liquid biopsy has the potential to identify resistance mutations and minimal residual disease, which can aid in personalized treatment strategies, leading to improved patient outcomes and reduced healthcare costs.

There was a growing emphasis on non-invasive diagnostic methods, such as liquid biopsies, for early detection and monitoring of breast cancer.

North America led the way with a strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe demonstrated significant growth due to increased awareness, supportive government initiatives, and rising research and development activities. The Asia-Pacific region exhibited substantial potential, driven by a large patient pool, expanding healthcare expenditure, and increasing focus on personalized medicine. Latin America and the Middle East/Africa regions also experienced a gradual uptick in liquid biopsy adoption, with improving healthcare facilities and a greater emphasis on cancer diagnostics.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Liquid Biopsy Market
Buy Now GET FREE SAMPLE
Breast Biopsy Market
Buy Now GET FREE SAMPLE
Breast Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Breast Cancer Market
Buy Now GET FREE SAMPLE
Vacuum-Assisted Breast Biopsy Device Market
Buy Now GET FREE SAMPLE
Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Breast Imaging Technologies Market
Buy Now GET FREE SAMPLE
Next Generation Cancer Diagnostics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Breast Cancer Liquid Biopsy Market
Breast Cancer Liquid Biopsy Market

Report ID: SQMIG35J2098

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE